G2G Bio

G2G Bio is a South Korean biotechnology company founded in March 2017 by CEO Heeyong Lee, who has over three decades of experience in new drug development and commercialization. The company specializes in developing sustained-release drug delivery systems for chronic diseases, aiming to improve patient compliance and convenience by reducing the frequency of administrations.

The core of G2G Bio's offering is its proprietary Innovative Long-Acting Microsphere Platform (InnoLAMP). This technology encapsulates peptides or small molecules into uniform, biodegradable microspheres that gradually release a drug over weeks or months following a single injection. The InnoLAMP platform is designed to achieve a high drug-loading capacity, improve bioavailability, and minimize injection site reactions. The company also possesses large-scale manufacturing capabilities, claiming to have Korea's largest capacity for producing these uniform microspheres.

G2G Bio's business model involves developing its own pipeline of treatments and collaborating with global pharmaceutical companies. It has established partnerships with firms like Boehringer Ingelheim for the formulation development of long-acting injectable therapies. The company also engages in contract development and manufacturing (CDMO) services. Its development pipeline targets high-demand therapeutic areas including Alzheimer's disease (GB-5001), diabetes and obesity (GB-7001), and postoperative pain (GB-6002). The company has completed Phase 1 clinical trials for several of its candidates.

Keywords: long-acting injectables, drug delivery system, microsphere platform, chronic diseases, Alzheimer's treatment, diabetes treatment, peptide drugs, sustained-release formulation, InnoLAMP technology, biopharmaceutical, clinical-stage, Boehringer Ingelheim collaboration, CDMO, GLP-1, donepezil, semaglutide, biodegradable polymers, patient compliance, drug formulation, biotechnology